FDA

CAR-T therapy
#Biosyngen #CAR-T #Cell therapy #FDA #Head and neck cancer #Oncology #Solid tumours

CAR-T therapy for nasopharyngeal cancer enters Phase II trials

The US Food and Drug Administration (FDA) has approved a Phase II clinical trial for Biosyngen’s BRG01, an EBV-specific CAR-T cell therapy. This marks the first cell therapy to enter Phase lI trials in both the US and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal… Read More

#News #Regulatory

#Brain cancer #FDA #hepatitis #PTSD #Regulatory #Solid tumours

New DDW Highlights podcast: 12 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The news highlights this week all centre around significant US Food and Drug Administration… Read More

#News

#Brain cancer #FDA #hepatitis #PTSD #Regulatory #Solid tumours

New DDW Highlights vodcast: 12 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   The news highlights this week… Read More

#News

#Brain cancer #FDA #hepatitis #PTSD #Regulatory #Solid tumours

This week in drug discovery (5-9 August) 

News round-up for 5-9 August by DDW Senior Digital Content Editor Diana Spencer. The news highlights this week all centre around significant US Food and Drug Administration (FDA) regulatory decisions, including new approvals for drugs for solid tumours, hepatitis B and glioma. The top stories:… Read More

#News

Former soldier suffering from PTSD
#FDA #MDMA #Psychiatry #PTSD

FDA urged to approve MDMA-assisted therapy for PTSD

Two veteran advocacy organisations, Reason for Hope and the Veteran Mental Health Leadership Coalition, have issued a joint statement urging the US Food and Drug Administration (FDA) to approve MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Last month, an FDA Advisory Committee recommended against approval, with… Read More

#News #Regulatory

MRI of the brain showing glioblastoma
#Brain cancer #FDA #Oncology #Servier Pharmaceuticals

FDA approves oral therapy for Grade 2 IDH-mutant glioma

The US Food and Drug Administration (FDA) has approved Voranigo, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, indicated for the treatment of patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma. It is approved in patients with a susceptible IDH1 or IDH2… Read More

#News #Regulatory

Hepatitis B
#FDA #GigaGen #hepatitis #Phase I trial

Recombinant polyclonal drug trial for HBV gets FDA green light

The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. It is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic… Read More

#News #Regulatory

Child with retinoblastoma
#FDA #Oncology #Paediatrics #Rare disease #Theriva Biologics

Retinoblastoma therapy gets FDA rare paediatric drug designation

Theriva Biologics’ VCN-01 for retinoblastoma has been granted rare paediatric drug designation (RPDD) by the US Food and Drug Administration (FDA). The FDA grants RPDD for rare diseases (fewer than 200,000 affected persons in the United States) that are serious and life-threatening and primarily affect children… Read More

#News #Regulatory

#Alpha Cognition #Alzheimer's #Drug delivery #FDA #Neurodegenerative disorders

US regulator approves galantamine prodrug for Alzheimer’s

The US Food and Drug Administration (FDA) has granted approval for Alpha Cognition’s Zunveyl (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease (AD). Tolerability affects therapy adherence, with data showing that 55% of AD patients discontinue their medication after one year, mainly… Read More

#News #Regulatory

Woman with painful shoulder
#Chronic pain #Fast Track designation #FDA #Fibromyalgia #Tonix Pharmaceuticals

FDA fast-tracks first new fibromyalgia drug in 15 years

The US Food and Drug Administration (FDA) has granted Fast Track designation to Tonix Pharmaceuticals’ Tonmya (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia. Tonmya is a non-opioid, centrally-acting analgesic drug under development for treating fibromyalgia, which is a common chronic pain condition affecting mostly… Read More

#News #Regulatory

Leukaemia
#Acute Myeloid Leukaemia #Fast Track designation #FDA #Sumitomo Pharma

Acute myeloid leukaemia drug gets fast-tracked

The US Food and Drug Administration (FDA) has granted Fast Track designation to Sumitomo Pharma’s DSP-5336 for relapsed or refractory acute myeloid leukaemia (AML). The drug is intended for patients with a KMT2A rearrangement, also known as, mixed lineage leukaemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m). Read More

#News #Regulatory

CAR-T therapy
#CAR-T #Cell therapy #FDA #Kyverna Therapeutics #Regenerative Medicine Advanced Therapy

Kyverna receives advanced therapy designation for KYV-101

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kyverna Therapeutic’s CAR-T candidate KYV-101 for refractory stiff-person syndrome (SPS). KYV-101 is an autologous, fully human CD19 CAR-T cell product candidate for use in B cell-driven autoimmune diseases. Read More

#News #Regulatory

Gene therapy
#Asklepios BioPharmaceutical #FDA #Gene therapy #MHRA #Neurodegenerative disorders #Parkinson's

US and UK fast track designations for Parkinson’s gene therapy

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 has also been awarded the innovative medicine designation, the Innovation Passport by the UK’s Medicines and Healthcare products Regulatory Agency… Read More

#News #Regulatory

#FDA #Oncology #Prostate cancer #Syncromune

FDA grants Fast Track designation to prostate cancer treatment

Biopharmaceutical company Syncromune has had its lead-candidate for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) granted Fast Track designation by the FDA. Syncromune’s SYNC-T SV-102 therapy is a personalised treatment that comprises of an in situ vaccine via partial oncolysis of a tumour followed by intratumoral infusion… Read More

#Cancer Research #News #Regulatory

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Eli Lilly #FDA #Neurodegenerative disorders #Phase III trial

FDA approves second anti-amyloid beta antibody for Alzheimer’s

Eli Lilly’s anti-amyloid beta monoclonal antibody (mAb) Kisunla (donanemab) has become the second disease-modifying therapy for Alzheimer’s disease (AD) to reach the US market, following approval by the US Food and Drug Administration (FDA). It has been approved by the regulator for the treatment of patients… Read More

#News #Regulatory #Trending News